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COPING WITH CANCER: IMPROVING OUTCOMES
The diagnosis of cancer can lead to mild intermittent anxiety, however, some
patients become clinically depressed. Depression is a psychological comorbidity, and
patients with comorbidities, physical or psychological in nature, are less compliant with
diagnostic and treatment regimens. Co-morbidities compromise the ability to adjust to
difficult changes. The result is decreased quality-of-life, and the effects can last long
after treatment ends (Badger, Braden, Mishel, & Longmann, 2004). Stress and anxiety
are a normal response to change or crisis. However, depressive symptoms should alert
practitioners to something more serious.
Depression ranks in the top ten of the most bothersome symptoms for those with
illnesses at an advanced stage, including cancer (Hotopf, Chidgey, Addington-Hall, &Ly,
2002). Depression has a negative effect on quality of life; it reduces the ability to enjoy
life, decreases survival time, and intensifies pain (Ciaramella & Poli, 2001). Despite the
high incidence and devastating consequences of depression among patients with cancer,
under-recognition and inadequate treatment are common. Grief is a normal reaction to
advanced cancer and the loss of health, autonomy, and functional ability (Bowers &
Boyle, 2003). Depression, however, is more intense and debilitating and can overpower
patients’ coping abilities.
The adverse impact of depression on cancer patients lives includes more frequent
exacerbations of chronic illnesses, anxiety, substance use, and an overall decreased
quality of life (Baum & Andersen, 2001). Depressed cancer patients may also experience
decreased immune system functioning, rapid onset of symptoms, increased metastasis,
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and higher rates of mortality compared to those cancer patients without depression
(Ciaramella & Poli, 2001; Hopko, 2008; Spiegel & Giese-Davis, 2003).
A major depressive episode is defined by DSM-IV as experiencing either
“dysphoria or anhedonia along with at least five somatic symptoms for at least two
weeks” (American Psychiatric Association, 2000). Anhedonia is defined as a loss of
ability to experience pleasure in things and accompanying loss of interest (Clarke,
Kissane, Trauer, & Smith, 2005). A collection of psychological and physical symptoms
indicate depression. These include depressed mood, loss of pleasure, difficulty
concentrating, appetite changes, sleep disturbance, and weight loss (American Psychiatric
Association, 2000). However, these somatic symptoms overlap with symptoms related to
cancer and cancer treatment, often leading to missed opportunities to diagnose and treat
depression. The challenge for practitioners is to evaluate and determine what is a
physiologic change related to cancer and its treatment and what is due to disabling
depression.
The ability to recognize symptoms of anxiety and clinical depression is key to
improving the quality of life for patients with cancer (Morgans & Schapira, 2011).
Unfortunately, up to half of the patients diagnosed with cancer and concomitant
depression are either undertreated or have no treatment at all (Gruneir, Smith, Hirdes, &
Cameron, 2005). A majority of medical oncologists have minimal, if any, formal
psycho-oncology training but are frequently confronted with patients who experience
mood and temperament changes and who can become disabled by psychiatric symptoms.
Recognizing patients at risk for the development of depression is important in order to
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improve outcomes. A systematic program for assessment and regular evaluation will aid
in identifying cancer patients who are at highest risk. (Morgans & Schapira, 2011).
Early identification and treatment of depression can result in positive outcomes.
A recent study on depressed cancer patients found that 50% of depressed cancer patients
experienced rapid improvement following behavioral therapy (Hopko, Robertson, &
Carvalho, 2009). Significant benefits were found early into therapy. Other studies have
reported similar findings (Aderka, Nickerson, Boe, & Hofmann, 2012).
Clearview Cancer Institute (CCI) is a private comprehensive cancer institute
serving thousands of cancer patients in north Alabama and the surrounding area.
Services provided include evidence-based medicine, clinical trials, nutritionist services,
massage therapy, multiple support groups, and patient education. To further improve
care to the patients, Coping with Cancer, an evidence-based program was implemented.
The goal was to improve outcomes through early recognition and treatment of depression
through a cognitive behavioral therapy program. In dealing with patients on a daily basis
it was evident that depression was a problem that was not being addressed effectively and
evidence showed adverse outcomes and decreased quality of life in those not adequately
treated. It also showed increased incidence of medical non-compliance though this was
not found to be the problem at CCI.
Review of Literature
The proposed program was developed using an "evidence-based methodology"
and included a systematic search of the literature and review with critique of the research
design, statistical results of relevant studies, and grading of the adequacy of the evidence
for drawing conclusions. The electronic database searches of CINAHL, PsycInfo,
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Cochrane Library for clinical trials, and MEDLINE were conducted. Search terms used to
identify primary research and relevant sources of secondary research were depression,
cancer, outcomes, anxiety, treatment, coping, screening and combinations thereof.
Articles included in the search were from 1994 to 2012.

The literature was

systematically reviewed based on the identified need for change of practice. National
guideline recommendations and expert consensus were also included in the formulation
of the recommendation.
Incidence and Effects of Depression
Polikandrioti et al. (2008) found that one out of two oncology patients are affected
by a psychological disorder with depression being the predominant condition. However,
despite the prevalence of depression in these patients, screening for depression was
inadequate, and the condition was undertreated. Risk factors for developing depression
include type of cancer, stage of disease, and years from onset of disease. Compounding
the problem of recognition of depression is differentiating the pathological symptoms
from those symptoms of the cancer itself (Polikandrioti et al., 2008).
Brown, Kroenke, Thobald, Wu, & Tu, (2010) in the Indiana Cancer Pain and
Depression (INCPAD) trial identified the adverse effect of depression on the health status
of patients. The impact was seen in patient vitality, general health, and overall quality of
life. It was found that while mild to severe anxiety was noted in approximately 30% of
patients, depression was more profoundly represented in 78%. This highlighted the
importance of identifying and treating both anxiety and depression within the oncological
population.
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Rayner, Price, Hotopf, & Higginson (2010) found that the consequences of
depression in patients with cancer compounds physical disability and increases pain and
fatigue. They also reported that those diagnosed with depression have poorer prognosis
and higher mortality rates.
Patients experience many losses during the course of a life threatening illness
such as cancer, thereby eliciting the grief response (Houston, 1999; Egan & Arnold,
2003). Patients experience preparatory or anticipatory grief related to the possibility of
death or separation resulting in a reaction of bereavement. Preparatory grief is noted to
be the normal grief reaction to perceived losses experienced by patients who are terminal
(Kubler-Ross, 1974). However, depression does not have to be a predictable aspect in
the process of dying. Depression, if recognized, is treatable (Hotopf, Chidgey,
Addington-Hall, & Ly, 2002).
A systematic review by Hotopf, Chidgey, Addington-Hall, & Ly (2002) found
that depression requires distinctive attention from providers of palliative care with an
emphasis on improving the quality of life for patients. There are very few disorders or
illnesses that are so strongly linked to a decreased quality of life as is depression.
Clinically, patients with depression and major illness experience significant reductions in
physical functioning. With the understanding that depression is treatable, it is imperative
that increased recognition of depression in patients with advanced disease be addressed to
improve quality of life and overall outcomes.
Cheng, Lo, Chan, Kwan, & Woo (2010) reported that grief, anticipatory or
current, is a process which all patients diagnosed with incurable cancer will experience.
The diagnosis itself was not seen as a definitive event, it was experienced as a process
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much like the stages of grief. Understanding the subjective experience of anticipatory
grief in these patients can contribute to developing psychotherapeutic interventions. As
patients approached the terminal stage, feelings of panic and fear were more prevalent.
Anticipatory grief was also found to contribute to the total pain reported by patients.
Interventions Effective In Reducing The Impact Of Depression
Cognitive Behavior Therapy (CBT) was developed from two earlier types of

psychotherapy: cognitive therapy, intended to change people’s thoughts, beliefs, and
expectations; and behavioral therapy, which helps people change actions (Wright, 2002).
The way one thinks about the situation affects how one will act. Actions will affect how
people feel. Consequently, it is necessary to change both the act of thinking and behavior
simultaneously. Focusing on overt behavior, acts that are obvious, as well as underlying
cognitions or thoughts help develop coping skills to achieve improved symptom control,
compliance, and overall improved outcomes (Mallick, 2009).
CBT is a method in which therapist and patient work together to recognize and
resolve issues or problems (Goldberg, 2012). Therapists use the method to help patients
deal more effectively with problems by changing ways of thinking, behavior, and
emotional responses. CBT has been shown to be effective in multiple psychiatric
disorders, including depression. Cancer-related research findings have included
cognitive interventions resulting in improved outcomes in physical and mental
functionality (Hopko et al., 2008). CBT has also been found to be a successful form of
treatment in sleep medicine (Morin, Colecchi, Stone, Sood, & Brink, 1999a).
Cognitive behavioral therapy is the most commonly used and evaluated
psychological therapy for the treatment of depression. The focus is on developing new

6

ways of thinking and reacting to situations in order to improve coping skills. In a Delphi
study, Rayner, Price, Hotopf & Higginson (2011) found cognitive behavioral therapy to
be the preferred choice of psychological therapy by experts in the palliative care setting.
Hodges et al (2009) used patient preference questionnaires to answer the
questions how, who, and where in regards to treatment of depression in cancer patients.
Patients first choice of “how” was talking therapy followed by talking and
pharmacotherapy combined. As noted previously, cognitive based therapy is talk
between therapist and patient to develop coping skills aimed at addressing patient
concerns and issues and changing ways of thinking and behavior. The National
Comprehensive Cancer Network (NCCN) Practice Guidelines recommend a step-up
approach for managing depression. Safety must be assured first, such as, ruling out risk
of suicide. Then pharmacologic therapy is suggested as an adjunct to psychotherapy,
with ongoing evaluation of effectiveness and appropriate modifications in the
management regimen (National Comprehensive Cancer Network, 2003).
Choice of Patient Health Questionnaire-9 Screening Tool
The Patient Health Questionnaire-9 (PHQ-9) is a nine-item survey for depression
derived from the complete PHQ. It is a self-administered survey. Major depression is
diagnosed if five or more of the nine depressive symptom criteria have been present more
than half the days in the past two weeks with one criterion being depressed mood or
anhedonia. Other depression is diagnosed if two, three, or four depressive symptoms have
been present more than half the days in the past two weeks with one being depressed
mood or anhedonia. One of the nine item indicators is thoughts of being better off dead or
of hurting oneself in any way. If present at all, irrespective of length of time, depression
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is diagnosed. Before the final diagnosis is made, the clinician must rule out physical
causes of depression and/or normal bereavement (Patient Health Questionnaire-9).
The PHQ-9 depression scale has been chosen as the screening tool for practical
reasons. It incorporates the diagnostic symptom criteria of the DSM-IV major depressive
disorder (Kroenke, Spitzer, & Williams, 2001). The items on the questionnaire are
related to the DSM-IV criteria enabling simple follow-up of symptom control (Spitzer,
Kroenke, & Williams, 1999). With only nine items, it is shorter than other depression
screening tools. It is unlike other depression screening tools in that it was developed and
specified for use in the medical population of patients with comorbidities. Validity was
established in the patient population with increased rates of physical symptoms and
accompanying broad-based psychological distress (Spitzer, Kroenke, & Williams, 1999).
The questionnaire can identify variances related to changes and effects related to
treatment (Lowe, Unutzer, Callahan, Perkins, & Kroenke, 2004) making it an excellent
choice as a clinical tool with longitudinal validity. Lee et al (2005) found that there is
broad use of the PHQ-9 in the medical setting.
Construct validity as a measure of the severity of depression was assessed by
examining functional status, disability days, symptom-related difficulty, and the
utilization of health care, such as, office visits (Kroenke, Spitzer, &Williams, 2001). A
strong relationship was found between higher PHQ-9 scores and decreased function.
Internal reliability of the PHQ-9 was high. In PHQ Primary Care Study it received a
Cronbach’s score of 0.89. Test and re-test reliability was also found to be excellent with
correlation between self-administered PHQ-9 survey and phone interview within 36
hours to be 0.84 (Kroenke, Spitzer, &Williams, 2001).
Guiding Theory & Conceptual Framework
8

The Kübler-Ross model of grief is the guiding theory and conceptual framework for the
project. The model deals specifically with the stages of grief which are commonly experienced
by patients who have been diagnosed with cancer. Grief is a frequent corollary of advanced
cancer and in this model is recognized as a process followed by those experiencing loss. This
model is commonly known as The Five Stages of Grief and more recently, The Five Stages of
Coping with Loss. Losses of health, autonomy, functional ability, roles, and relationships often
prompt significant sadness, a normal psychological response to loss. Once diagnosed, a patient
will enter into the denial phase and many thoughts and feelings will be dismissed, thereby
hindering ones’ ability to progress effectively through the normal stages leading to acceptance.
Depression is a possible phase of the grieving process and is a more intense and debilitating
version of sadness. It results from multiple factors that overwhelm the ability to cope with losses,
actual or anticipated, related to the diagnosis of cancer. It is, unfortunately, a stage in which
patients commonly become stagnant due to inadequate coping skills. This model, with its five
stages (denial, anger, bargaining, depression, acceptance), can be used to guide interventions for
those experiencing personal change and emotional upset resulting from factors other than death
and dying.
The Kübler-Ross model was proposed by Elisabeth Kübler-Ross based on her work with
terminally ill patients. Although the theory originally focused solely on those who were
terminally ill, it has been accepted for anyone experiencing a loss, supporting its beneficial use
with cancer patients. The stages are not a complete list of emotional behaviors of those
experiencing a life-altering event, nor are they chronological. Those experiencing a loss may
move in and out of each of the stages multiple times and in random order. However, it does serve
as a framework to guide the understanding of the complex set of emotions one experiences while
moving through the multifaceted landscape of loss, real or anticipated (Kübler-Ross, 1974).
Kübler-Ross did not expect the stages of grief to be an unyielding set of progressive or unvarying
phases individuals would pass through uniformly. It is not expected that all people will visit each
9

stage or that they will visit in the same order. The path through the grieving process is as
individual as the individuals themselves.
The grief cycle can be seen as a change model for aiding in the understanding and ability
to cope with distress, physical, or most importantly, emotional. It is not solely for death and
dying. Emotional distress and its response must not be regarded in absolute terms but understood
that it is relative and varies with the individual. The model is fluid in that it allows for personal
variability when dealing with life threatening illness and the associated emotional turmoil.
Patients in the Coping with Cancer sessions were guided in discussion using this model to
help them recognize problems and develop coping skills leading to the final phase of acceptance
facilitating overall improved depression scores and patient satisfaction (Figure 1).

Figure 1.
Stages of Grief Model

Denial

Sadness/
Depression

Acceptance

Bargaining
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Anger

Coping with Cancer Program

The Coping with Cancer program provides patients with the support and tools to
develop improved coping skills that foster increased enhanced medical compliance. It
also enables patients to understand the impact depression and distress have on their
psychological health and overall health outcomes.
Each session has a theme or topic which the program facilitator introduces and
then opens the floor for discussion. The topics are listed below in order of the weekly
sessions:
1. The Elephant in the Room – A few of the key points include
a. What makes it so difficult to talk about cancer?
b. Why are people reluctant to talk to you about your cancer?
c. How difficult is it to talk about your cancer as “the elephant in the room”?
d. What do you need most in dealing with the elephant in the room?
2. Why Do We Feel This Way? Think of the first time you heard the word cancer
from one of your doctors and ask yourself these questions:
a. What was going on in your life at that point in time?
b. What things were most important to you at that initial time? What were
your goals and aspirations for the future?
c. What were you living for at that time? Is it the same as today?
3. The Ups and Downs of Cancer – A few key points include
a. Your cancer can and will involve every facet of your life; physically,
mentally, spiritually and socially.
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b. What you think about your condition will have an effect on your outcome.
As how we feel emotionally will affect us in life.
c. “Feel what you feel” is good advice for every challenge you face. Putting
on façade will likely complicate progress. Recognizing negative feelings
will allow you to move on and progress.
4. How Cancer Affects Relationships and Where Do We Go From Here? Questions
and key points include
a. What details about your condition do you share with others?
b. What do you want to accomplish in talking about your cancer to others?
What do you want them to do with the information you share with them?
c. How much information is needed to be given?
d. Does each doctor visit need to be talked about with family?
e. Redefining roles, relationships, and what used to be and is now different
are changes that have to be dealt with in the family unit. These change
from questions to statement—need to be consistent or give explanation
f. Sharing sorrows and joys yields a return of healing and intimacy.
g. Finally, the message “Life goes on” takes on deeper meanings as we
confront crisis.
Several key points or questions are presented and patients are then encouraged to
participate or observe depending on their level of comfort. The program facilitator
allows each patient to express their feelings openly while keeping the discussion focused
and productive for all those present. The goals of sessions one and two were to help
patients recognize their diagnosis and its’ possible impact on their lives. It was meant to
12

begin addressing denial and anger seen in the Grief Model. The goals of sessions three
and four were to continue recognizing feelings and adjust to changes allowing them to
move on through the phases of bargaining and depression leading eventually to
acceptance. The sessions were designed for patients to recognize feelings and behaviors
that may not have previously been apparent.
The CBT program, different from typical support groups, sets itself apart in that it
is facilitated by a licensed counselor who uses the above plan for each session. Patients
are encouraged to participate as it is a group program but the facilitator keeps the group
focused and guides participants towards the goal of acceptance. The facilitator was Ron
Williams, a local minister who graduated from Freed-Hardeman University with a B.A.
degree in Bible and received his Masters of Science in Counseling from Southern
Christian University in Montgomery, AL. Ron has served as a member of the FHU
Advisory Board and is a chaplain for the Alabama Department of Public Safety and State
Trooper Office for Madison County. He has served as Associate Chaplain for Crestwood
Medical Center. He is a certified hospice worker and a co-author of the book, Walking
with Those Who Weep: A Guide to Grief Support (1996).
Sessions are held at Clearview Cancer Institute in a private room that can
accommodate approximately 50 people. It was reserved for Coping with Cancer each
Friday. The room is secluded on the third floor featuring a window that runs the length
of the entire room providing a spectacular nature filled view. Patients were seated at
tables with ample personal space. Each participant was provided with a folder of topic
outlines and a notebook to keep track of points of interest.
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Patients were identified initially through their diagnoses of stage IV disease with
head and neck, pancreatic, lung or breast cancer. These were identified by practitioner
referral or through the electronic medical record system report generator. Patients were
provided with an informational packet by mail and a follow up phone call to address any
questions prior to beginning the program. Informed consent was obtained once patients
agreed to participate in the program. Following informed consent patients were then
screened for depressive symptoms using the PHQ-9 screening tool. Patients who scored
five or above automatically met criteria and were enrolled and scheduled to attend the
four weekly one-hour sessions.
Implementation Procedures
The procedures for this project are outlined below:
1. Received approval from University of Alabama Huntsville Institutional
Review Board.
2. Obtained permission from the physicians and Chief Operating Officer at
Clearview Cancer Center to recruit stage IV head and neck cancer, pancreatic,
breast, and lung cancer patients for participation in the program.
3. Identified patients for participation based on stated criteria. Patients were
identified through practitioner referrals and the institutions electronic medical
record system by diagnosis and stage of disease.
4. Conducted informational session with identified patients to assess willingness
to participate in program.
5. Obtained informed consent.
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6. Completed depression screening with PHQ-9 survey to identify patients
meeting inclusion criteria.
7. Enrolled patients in program sessions.
8. Administered repeat PHQ-9 depression survey at end of the program and at
one month post program completion.
9. Obtained patient satisfaction survey for evaluation of program efficacy.
10. Summarized results of program implementation and evaluation.
Evaluation
The purpose of the evaluation plan was to determine effectiveness of the
evidence-based program. Evaluation included depression scores on repeat PHQ-9
survey, patient compliance with appointments, and diagnostics, and overall patient
satisfaction.
The specific goals were:
a. To ensure that at-risk patients were identified according to program criteria;
b. To screen patients meeting initial criteria with PHQ-9 depression screening tool;
c. To enroll patients meeting criteria in the program;
d. To evaluate the effectiveness of the program through repeat PHQ-9 survey;
e. To evaluate the effectiveness through increase medical compliance with plan of
care including office visits, treatment regimens, and diagnostics;
f. To measure the patient satisfaction through use of patient satisfaction survey.
Evaluation Questions
Patients were identified for eligibility by diagnosis of stage IV disease and
referred directly to the program from practitioners or through generated reports from the
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electronic medical record system at Clearview Cancer Institute.
Upon evaluation of patient attendance and willingness to participate, it was found
that direct referrals were most effective. Patients who were referred by the practitioners
were more likely to participate in the program. The generated reports by disease and
stage were helpful in identifying those at risk for depression; however, due to the delicate
nature of the program, a personal referral had a greater positive impact than cold calls or
mailings. There were numerous patients who expressed interest in participating, however,
due to treatment regimens or debility were unable to participate. For these patients future
sessions will be an option.
Compliance with the program was part of the evaluation process as well. Once
enrolled, patients were found to be enthusiastic about the program and attended sessions
regularly. If a patient had to miss a session due to illness or treatment, the facilitator or
other group participants were notified. The commitment to program sessions was
overwhelmingly positive.
Assessment of PHQ-9 scores was an integral part of the overall program
evaluation. The initial PHQ-9 scores ranged from 5 to 12 out of a possible 27. The
higher the score the more severe depression is noted. The initial findings are based on
two sessions with a total of eight participants. Out of the eight scores used for evaluation
there was found to be improvement in six of the repeat PHQ-9 scores. The scores
improved an average of 3.4 points. One participant’s score remained the same and the
other increased by one point (Table 1).
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Table 1
Pre and Post PHQ-9 Scores
Participant # Initial Score

Final Score

1

5

2

2

8

4

3

7

8

5

10

4

6

10

10

7

12

6

8

12

3

Total Scores

64

37

8

4.6

Average Score

Two patients did not score a five or above on the PHQ-9 and were allowed to
participate at their own request. Their information was not used to report findings for the
program but will be discussed as their participation proved to be important throughout the
program. The two participants who did not initially score five or above, scored five and
12 on completion of their sessions, an increase in each of their scores. Each explained
that prior to the program they were in a state of denial regarding their diagnosis and their
emotional state. Participating in the sessions enabled them to recognize the denial which
lead to higher scores on the repeat PHQ-9 surveys. Despite the increase in pre and post
PHQ-9 scores the patient satisfaction surveys demonstrated a high level of satisfaction
with the program overall.
One evaluation question addressed patient medical compliance. On review of the
number of patient “no shows” to office visits and scheduled diagnostics during and
following the program the patients who participated were found to have 100%
compliance. Though this was not a problem found in patients participating in this
17

program it was mentioned in the literature. The review of records was done using the
electronic medical record system.
It is important that those involved in the practice change, from clinicians to
patients, provide input related to changes. The Model for Evidence-Based Practice
Change states that continuous feedback be solicited from those involved in the change
(Melynk, Fineout-Overholt, 2010). Outcomes and benefits along with the actual change
of practice should be the primary focus.
The change process was monitored and evaluated throughout the entire process.
Evaluation for program effectiveness was an ongoing process with each weekly session
and has been an invaluable component to the program’s success. The facilitator kept
detailed notes on patients’ verbal feedback during sessions. The feedback was
predominantly positive with comments related to patient satisfaction with the program
and its’ effects on their lives and that of their families. No written feedback was obtained
during sessions.
Likely the most valuable tool in the evaluation process has been the patient
satisfaction survey which had a possible high score of 16. Out of the eight surveys of
those who qualified with PHQ-9 screening, six gave a total point score of 16 while the
other two gave a total of 14 points each. The two participants not qualifying with PHQ-9
scoring gave the program a 16 and each recommended that follow-up sessions be offered
for those completing the program.
Included in the survey were two sections for personal feedback. The first question
“Would you recommend this program to family and friends?” was unanimously positive
for those qualifying and those who did not. The second question “Suggestions to
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improve the Coping with Cancer program…” elicited no specific suggestions for
improvement of the program as it is now. Comments from the participants were the
following:
1. “Do not change a thing, it is perfect the way it is!”
2. “Extend the program…offer more than four sessions.”
3. “The program should be available to all patients.”
4. “Keep class size small, more personal”
5. “Keep the program going”
6. “The program is an invaluable service to patients”
7. “A class for family members should be made available also.”
8. “Class facilitator is very genuine”
9. “Class facilitator is easy to talk to”
On the patient satisfaction surveys one of the most positive components of the
program was the ability of the facilitator to make everyone feel welcome and the ability
to keep the discussion moving along. Discussions were not allowed to become stagnant
or side-tracked from the topic at hand. This was valuable to the patients. They reported
that they felt as if their time was well spent, and one patient reported that “my family has
blocked off my schedule for Friday mornings because when I come home I am so much
happier…they do not want anything to conflict with this class.”
As a result of the promising responses noted to the initial sessions, the Coping
with Cancer program will continue to be offered on a regular basis to patients. As
suggested in the patient satisfaction survey, the program will be extended to six weekly
sessions instead of four. A follow-up class will be offered once a month for those
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completing the program for continued support and will be open to all participants. This
session will also be held with the original program facilitator. To sustain continual
success of the Coping with Cancer program, evaluation criteria in the initial proposal will
be continued with no change at this time. Funding will continue to be sought through
The Russell Hill Cancer Foundation.
Effectiveness was demonstrated by improved PHQ-9 scores, continued referrals
to the program by practitioners based on positive feedback from participants, and high
levels of patient satisfaction reported on end of program patient satisfaction surveys.
Patients are automatically eligible for the program if meeting set diagnosis criteria;
however, as noted in the initial sessions, participation is more consistent when the patient
is referred directly by the physician or nurse practitioner. As noted above, patient
referrals are ongoing, demonstrating the effectiveness of the program based on patient
feedback to practitioners. Patients who agreed to participate attended each scheduled
session unless scheduled for treatment on that day or due to sickness.
The program cost was funded by a grant from The Russell Hill Cancer
Foundation. Total cost of the program was $1,000 per four week session broken down as
seen below:
Counselor Fee

$400

Advertisement Costs

$400

Miscellaneous

$200

Total

$1,000

The fee for the counselor was for the complete four week session. Advertisement costs
will be ongoing as flyers and mailings will be used with each session. Miscellaneous
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costs will include any supplies for the classes including folders, notebooks, and pens.
Each participant is provided with a packet when starting the session.
Potential Barriers
The principal barrier as suggested in the initial proposal was the willingness of patients to
participate in the program. Due to inclusion criteria of stage IV disease which was noted in the
literature as those patients at highest risk for depression, these patients had been through multiple
treatment regimens and were not willing to commit to the program due to declining health and
physical limitations. A common misconception about the program was that it was a support
group. Many of those contacted for participation refused due to this reason. However, this
barrier has been addressed by continued discussions and follow-up with nurse practitioners,
physicians, and staff regarding the focus of the program.

Expansion
The Coping with Cancer program will continue to be provided to the patients and
family members at Clearview Cancer Institute. The program addressed a need within the
oncological population as well as the needs of their family and caregivers. The
participants expressed a need for a similar program for their families and caregivers. It
was suggested that family and caregivers have a different class for the benefit of all.
Patients felt that they needed privacy from their loved ones to be able to speak openly and
frankly about difficult situations that sometimes involve those they love the most.
Therefore, a brief proposal was submitted as a complement to the Coping with Cancer
program for patients. The proposal suggested Coping with Cancer: Family, a concurrent
session for family and caregivers. The initial session for Coping with Cancer: Family
was a success with four participants. Funding for this program was not needed as the
facilitator was a volunteer. Future funding, if needed, would likely be sought from the
21

Russell Hill Cancer Foundation. Another opportunity for expansion has been the
monthly follow-up session for those who have completed the program. The program
facilitator met once a month with those who have completed the program. A very close
bond was formed among the participants, and they expressed a desire to continue to meet
as a group with the facilitator upon completion of the program.
Dissemination

Plans to disseminate the results of the Coping with Cancer program include
submission of a manuscript to a peer-reviewed journal such as Journal of the Advanced
Practitioner in Oncology, Clinical Journal of Oncology Nursing, or Oncology Nursing
Forum. Another excellent opportunity for dissemination would be to present a poster at a
local, regional or national oncology conference.

Role of DNP
It was clear that patients were negatively impacted by depression and there was a
real need to address this issue. DNP’s are in the unique position of recognizing the needs
and often challenging issues of patients. To formulate solutions once a need has been
identified DNP’s look to the evidence. Understanding that there is often a gap between
research and practice; DNP’s are able to develop processes that will bridge this gap and
offer patients the best possible care. Coping with Cancer is one of the evidence-based
initiatives that is bridging the gap.
Conclusion
Depression is a significant co-morbidity in those with cancer. Gruneir, Smith,
Hirdes, & Cameron (2005) reported that up to half of the patients diagnosed with cancer
and concomitant depression are either undertreated or have no treatment at all.
Understanding the detrimental role depression plays in the lives of these patients is key to
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identifying and addressing the problem. The PHQ-9 was an excellent tool to effectively
identify depression in cancer patients as it was developed and specified for use in the
medical population of patients with comorbidities (Spitzer, Kroenke, & Williams, 1999).
Hodges et al (2009) found that patient preference in the treatment of depression was
“talk” therapy which is the basis for CBT in which the patient and therapist discuss
issues. Evidence has shown that CBT is instrumental in helping patients change their
way of thinking leading to improved coping skills and overall outcomes. Coping with
Cancer has been shown to improve depression based on improved PHQ-9 scores, patient
satisfaction surveys, and medical compliance. The program has proven to be a cost
efficient and easily managed approach to address the issue of depression in cancer
patients.
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APPENDIX

Patient Health Questionnaire 9 (PHQ-9)
Name ____________________________________________ Date ________________
More than
Over the last 2 weeks, how often have you been bothered Not Several
Nearly
half the
by any of the following problems?
at all
days
every day
days
1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself—or that you are a failure or
have let yourself or your family down

0

1

2

3

7. Trouble concentrating on things, such as reading the
newspaper or watching television

0

1

2

3

8. Moving or speaking so slowly that other people could
have noticed? Or the opposite—being so fidgety or
restless that you have been moving around a lot more than
usual

0

1

2

3

9. Thoughts that you would be better off dead or of
hurting yourself in some way

0

1

2

3

(For office coding: Total Score ____ + ____ + ____ = ____)

If you checked off any problems, how difficult have these problems made it for you to do
your work, take care of things at home, or get along with other people?
Not difficult
□

Somewhat difficult

Very difficult

□

□
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Extremely difficult
□

COPING WITH CANCER

ADDRESSING THE INDIVIDUAL NEEDS
OF PATIENTS
“CCI strives to provide patients with the highest
quality care…Coping with Cancer is another
way we are achieving this goal.”

 Learning more about ways you can help yourself
may ease some of your concerns.
 Your treatment may change, but as always, you
will continue to receive the best medical
attention from your health care team and
support from your caregivers.
 It’s important to talk about your worries,
frustrations, and problems, and get support
from others. In fact, it may be one of the best
things you can do for yourself.
 As your health care condition changes, you have
many choices. You can choose the way you wish
to live each day

 Gaining a sense of
empowerment and
control
 Improved coping skills
and adjustment
 An opportunity to talk
openly and honestly
about feelings in a
warm, inviting
environment
 Reduction in distress,
depression or anxiety
 Sharing experiences of
life valuable to
therapeutic adjustments
 Lending support,
encouragement, and
hope
 Enhancing self-esteem

Weekly sessions each Friday in the East Room 2nd Floor10:00am to 11:00am
29 contact
For more information please
Deborah Abu-Alrub, CRNP @ 256-705-4224

COPING WITH CANCER
FAMILY
ADDRESSING THE NEEDS OF P ATIENTS
FAMILY AND FRIENDS
“CCI strives to provide patients and their families with
the highest quality care…
Coping with Cancer, Family is another way we are
achieving this goal.”
 Learning more about ways you can help yourself may
ease some of your concerns.
 It’s important to talk about your worries, frustrations,
and problems, and get support from others. In fact, it
may be one of the best things you can do for your
loved one and yourself.
 Thinking and talking about your feelings can be hard;
it is helpful to find ways to express your feelings.
 Recognize that your loved one’s progress is not a
reflection of your caregiving. Uncertainties and highs
and lows are part of dealing with cancer – no one, not
even the best caregiver, can control them

 An opportunity to talk
openly and honestly about
feelings in a warm,
inviting environment
 Recognize and respect
your own feelings, needs,
and desires, as well as
those of the patient.
 Gaining a sense of
empowerment and control
 Improved coping skills and
adjustment
 Reduction in distress,
depression or anxiety
 Sharing experiences of life
valuable to therapeutic
adjustments
 Lending support,
encouragement, and hope

Weekly sessions each Friday in the Board Room 2nd Floor10:00am to 11:00am
For more information please contact
Deborah Abu-Alrub, CRNP @ 256-705-4224
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COPING WITH CANCER
PATIENT SATISFACTION SURVEY

Help us better serve you.
By filling out this survey you can help us improve this program
and allow us to continue providing you with high quality
health programs.
All survey information is strictly confidential.
Patient Name _____________________________________
4
Excellent

3
Good

2
Fair

1 Did the program help me?
2 Was the information in the
program important for
me?
3 Was the facilitator
helpful?
4 Was the format and time
of program convenient?
5 Was the program
explained adequately prior
to enrollment?
6. Would I recommend the program to family and friends?
____________________________________________________
7. Suggestions to improve the Coping with Cancer program…
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1
Poor

Implementation Plan
1. Patient will be identified for possible inclusion in program by
diagnosis and staging. Report of patients meeting the below
criteria will be generated using electronic medical record.
a. Head and neck cancers
b. Lung
c. Pancreatic
d. Breast
e. Stage IV defined as disease with distant metastasis and
failure on first line therapy
2. Patients identified above will be provided with written
program information and verbal education.
a. Nurse practitioners will facilitate patient education and
enrollment.
3. Patients interested in participating in the program will
provide informed consent.
4. PHQ-9 depression survey will be completed. Patients
scoring 5 or higher will be enrolled into the program.
5. After completing program sessions, patients will complete a
repeat PHQ-9. A repeat PHQ-9 survey will be completed 1
month post program.
6. Patient satisfaction survey will be completed at the end of
program.
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CLEARVIEW CANCER INSTITUTE
INFORMED CONSENT FORM

Informed Consent Form for Coping with Cancer Pilot Program
Informed consent obtained for use of Clearview Cancer Institute only who are inviting patients to
participate in the Coping with Cancer program.
Name of Principle Investigator: Deborah S. Abu-Alrub, CRNP
Name of Organization: Clearview Cancer Institute
Name of Sponsor: Clearview Cancer Institute
Name of Project and Version: Coping with Cancer, Pilot Program
Part I: Information Sheet
Introduction
I, Deborah S. Abu-Alrub, CRNP, working for Clearview Cancer Institute. am initiating the Coping
with Cancer pilot program designed to improve patient care and outcomes by helping patients develop
much needed coping skills to deal with the diagnosis of cancer.
Purpose
To decrease the impact of depression on cancer patients here at Clearview.
Type of Research Intervention
Coping with Cancer is a behavioral therapy program with 4 weekly sessions of one hour each.
Patients who choose to participate will meet with a licensed counselor to discuss the impact cancer has
on their lives. They will have the added benefit of hearing from other patients at Clearview as well.

Participant Selection
You are being invited to participate in this program based on your cancer diagnosis and we feel that
you will likely benefit from the program.

Voluntary Participation
Your participation in this program is entirely voluntary. It is your choice whether to participate or not.
If you choose not to participate all the services you receive at Clearview will continue and nothing will
change.

Procedures
A. You will be asked to participate in weekly group sessions discussing the effects the diagnosis of
cancer has on your life and ways to manage these effects.
B. You will be asked to fill out a survey, the PHQ-9, at the beginning of your sessions which will be
provided by Ron Williams, session facilitator.
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If you do not wish to answer any of the questions included in the survey, you may skip them and
move on to the next question. The survey will be provided to you individually and collected
individually by Ron to ensure the privacy of all participants. The information recorded is confidential,
your name is not being included on any program information hereafter, only a number will identify
you, and no one else except I, Deborah S. Abu-Alrub, CRNP, and Ron Williams will have access to
your survey.
You will take part in a group session with 8-10 other persons with a similar diagnosis. This discussion
will be guided by Ron Williams. The group discussion will start with making sure that you are
comfortable. He can also answer questions about the program that you might have. Then he will begin
the session with pre-planned program material to facilitate discussion for each session. We will not
ask you to share personal beliefs, experiences, or stories and you do not have to share any
knowledge that you are not comfortable sharing. The discussion will take place in the East Room
and no one else but the people who take part in the sessions will be present. At the end of your 4 week
session, a repeat PHQ-9 survey will be completed to evaluate the value of the session. You will also
be asked to complete a patient satisfaction survey to help further improve the program.
Duration
The program will be held in one hour increments with four weekly sessions. You are then welcome to
participate further at your own discretion.
Risks
We may be asking you to share with us some very personal and confidential information, and you may
feel uncomfortable talking about some of the topics. You do not have to answer any question or take
part in the discussion/interview/survey if you don't wish to do so. You do not have to give us any
reason for not responding to any question, or for refusing to take part in the discussion.
Benefits
By participating in this program you may gain valuable coping skills that will allow you to deal more
effectively with your diagnosis of cancer and its implications in your life. You may also gain
emotional support from the facilitator or other members in the session through an opportunity to talk
openly and honestly about feelings in a warm, inviting environment. You may experience a reduction
in stress and anxiety. You may also develop a sense of control and empowerment.
Reimbursements
You will not be provided any incentive to take part in the program.
Confidentiality
The program sessions and all participants are strictly confidential on the part of Clearview.
Participants will be known by a number for the purposes of data collection. Personal information will
not be shared with anyone except those stated above. We will ask you and others in the group not to
talk to people outside the group about what was said in the group. We will, in other words, ask each of
you to keep what was said in the group confidential. You should know, however, that we cannot stop
or prevent participants who were in the group from sharing things that should be confidential.

Sharing the Results
Nothing that you tell us will be shared with anybody outside the program facilitator and Clearview,
and nothing will be attributed to you by name. The knowledge that we get from this program will be
shared with Clearview Physicians and Nurse Practitioners to summarize results and review
effectiveness of the program.
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Right to Refuse or Withdraw
You do not have to take part in this program if you do not wish to do so, and choosing to participate or
not will in no way affect your current care. You may stop participating in the program at any time that
you wish without your care being affected.
Who to Contact
If you have any questions, you can ask them now or later. If you wish to ask questions later, you may
contact any of the following: Deborah S. Abu-Alrub, CRNP @ 256-705-4224.
This proposal has been reviewed and approved by University of Alabama in Huntsville IRB, which is
a committee whose task it is to make sure that research participants are protected from harm. If you
wish to find about more about the IRB, contact University of Alabama in Huntsville.

 Do you know why we are asking you to take part in this study? Do you know what the study
is about?
YES NO
 If you decide to take part in the program, do you know how much time will be required?
YES NO
 Where will it take place?
YES NO
 If you agree to take part, do you know if you can stop participating?
YES NO
 Do you know that you may not respond to the questions that you do not wish to respond to?
YES NO
 Do you know that you do not have to take part in this research study, if you do not wish to?
YES NO
 Can you tell me if you have understood correctly the benefits that you will have if you take
part in the study?
YES NO
 Do you know if the study will pay for your travel costs and time lost, and do you know how
much you will be reimbursed?
YES NO
 Did you understand the procedures that we will be using to make sure that any information
that we collect about you will remain confidential?
YES NO
 Do you understand that we cannot guarantee complete confidentiality of information that
you share with us in a group discussion?
YES NO
 Do you have any more questions?
YES NO
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Part II: Certificate of Consent
I have been invited to participate in the Coping with Cancer pilot program at Clearview Cancer
Institute.
I have read the foregoing information, or it has been read to me. I have had the opportunity to
ask questions about it and any questions I have been asked have been answered to my
satisfaction. I consent voluntarily to be a participant in this study

Print Name of Participant__________________
Signature of Participant ___________________
Date ___________________________
Day/month/year

Statement by the researcher/person taking consent
I have accurately read out the information sheet to the potential participant, and to
the best of my ability made sure that the participant understands that the above
mentioned will be done.
I confirm that the participant was given an opportunity to ask questions about the study, and all
the questions asked by the participant have been answered correctly and to the best of my
ability. I confirm that the individual has not been coerced into giving consent, and the consent
has been given freely and voluntarily.
A copy of this ICF has been provided to the participant.
Print Name of Researcher/person taking the consent________________________

Signature of Researcher /person taking the consent__________________________
Date ___________________________
Day/month/year
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